Open AccessAn experience of therapy of patients with chronic obstructive pulmonary disease and metabolic syndrome with selective phosphodiesterase-4 inhibitor roflumilast
Author(s) -
Г. Л. Игнатова,
Е В Блинова,
Maria S. Belsner,
Irina Grebneva
Publication year - 2016
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2016-26-3-323-327
Subject(s) - roflumilast , medicine , exacerbation , copd , spirometry , metabolic syndrome , body mass index , gastroenterology , obesity , asthma
The aim of this study was to evaluate clinical efficacy and safety of selective phosphodiesterase"4 inhibitor roflumilast in patients with COPD and metabolic syndrome. Methods . In this prospective study, patients with stage III – IV COPD, frequent exacerbation phenotype (≥ 2 per a year) and metabolic syndrome (n = 42) were treated with roflumilast (Daxas) 500 mg q.d. additionally to the basic therapy for 12 months. Clinical investigation, mMRC scale and CAT questionnaire, pulse oxymetry, spirometry, 6"min walking test, measurement of glucose, lipids and C"reactive protein in blood were used in all patients. Results. Exacerbation rate decreased in patients with COPD treated with roflumilast. FEV1 and quality of life improved in patients treated with roflumilast. Therapy with roflumilast was associated with statistically significant reduction in the waist circumference without significant change in the body weight, waist"to"hip ratio or body mass index. Conclusion . Therapy with roflumilast was associated with improvement in clinical, laboratory and functional parameters and reduction in exacerbation rate in patients with COPD and metabolic syndrome.